番茄社区app

Novel CD19xCD3 T-cell engager showed high response rate in phase I study

Promising single-agent efficacy with manageable safety may reshape initial treatment

Experts talk about long-term data and the importance of infection prophylaxis

"Safety profile is one of the real advantages" of non-covalent BTK inhibitor, says panelist

Study results show impressive efficacy, favorable safety profile in the second line

Our panel of experts discuss 3-year findings from the phase II ELARA study

Bispecific antibody also shows high response rates in frontline setting

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD

Ian Flinn, MD, leads a roundtable discussion with Loretta Nastoupil, MD, and Amitkumar Mehta, MD